Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Tempus AI, Inc. - Class A Common Stock (NQ:TEM)

44.34 -1.14 (-2.51%)
Streaming Delayed Price Updated: 10:56 AM EDT, May 15, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Tempus AI, Inc. - Class A Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
Tempus Expands Strategic Collaboration with Bristol Myers Squibb to Enhance the Probability of Success Across Clinical Development Programs In Oncology and Neuroscience
From Tempus AI, Inc.
Via Business Wire
TechMediaBreaks – MindBio Therapeutics Corp. (CSE: MBIO; Frankfurt: WF6; OTCQB: MBQIF) Advances AI Voice-Based Intoxication Detection as Real-Time Diagnostics Market Expands
Via Investor Brand Network
Topics Artificial Intelligence
The Future of Intoxication Detection May Be in Your Voice
Via Investor Brand Network
Topics Artificial Intelligence
News headline image
The Future of Intoxication Detection May Be in Your Voice
From BioMedWire
Via GlobeNewswire
News headline image
Ambry Genetics’ CARE Program® Wins 2026 MedTech Breakthrough Award for “Best Overall Health Informatics Solution”
From Ambry Genetics
Via Business Wire
News headline image
Tempus Announces Pricing of Upsized Offering of $400.0 Million of Convertible Senior Notes
From Tempus AI, Inc.
Via Business Wire
News headline image
Tempus AI, Inc. Announces Proposed Convertible Senior Notes Offering to Optimize Capital Structure and Reduce Interest Expense
From Tempus AI, Inc.
Via Business Wire
News headline image
Tempus Reports First Quarter 2026 Results
From Tempus AI, Inc.
Via Business Wire
News headline image
Tempus to Host Inaugural Investor Day on May 29, 2026
From Tempus AI, Inc.
Via Business Wire
News headline image
Tempus Named to TIME's 10 Most Influential Health and Life Science Companies of 2026
From Tempus AI, Inc.
Via Business Wire
News headline image
Tempus and USC Announce Strategic Collaboration to Accelerate AI-Driven Precision Medicine
From Tempus AI, Inc.
Via Business Wire
News headline image
Tempus to Report First Quarter 2026 Financial Results on May 5
From Tempus AI, Inc.
Via Business Wire
News headline image
Tempus and Predicta Biosciences Announce Collaboration to Expand Life Sciences Access to Ultrasensitive Whole-Genome Sequencing Assay for Hematologic Malignancies and MRD Monitoring
From Tempus AI, Inc.
Via Business Wire
News headline image
Tempus Announces 31 Abstracts for Presentation at the American Association for Cancer Research Annual Meeting 2026
From Tempus AI, Inc.
Via Business Wire
News headline image
Tempus Launches Automated “Active Follow-Up” Service to Support Guideline-Concordant Care
From Tempus AI, Inc.
Via Business Wire
News headline image
Tempus Announces Strategic Collaboration with Gilead to Advance Oncology R&D Through RWE
From Tempus AI, Inc.
Via Business Wire
News headline image
Tempus to Present at the 25th Annual Needham Virtual Healthcare Conference
From Tempus AI, Inc.
Via Business Wire
News headline image
Tempus and Medtronic Announce ALERT Trial Results Showing AI-Driven EHR Notifications Improve Treatment for Significant Valvular Heart Disease
From Tempus AI, Inc.
Via Business Wire
News headline image
Tempus and Blood Cancer United® Announce Collaboration to Develop One Of the Largest Pediatric Acute Myeloid Leukemia Real-World Data Registries
From Tempus AI, Inc.
Via Business Wire
News headline image
Tempus Announces Study Highlighting the Role of Advanced Genomic Profiling Features in Identifying Clinically Actionable Findings
From Tempus AI, Inc.
Via Business Wire
News headline image
Tempus Announces Strategic Collaboration Agreement with Merck to Accelerate AI-Driven Precision Medicine
From Tempus AI, Inc.
Via Business Wire
News headline image
Tempus to Participate in the Morgan Stanley Technology, Media & Telecom Conference
From Tempus AI, Inc.
Via Business Wire
News headline image
Tempus Reports Fourth Quarter and Full Year 2025 Results
From Tempus AI, Inc.
Via Business Wire
News headline image
Tempus Announces Novel Pan-Cancer HRD-RNA Algorithm
From Tempus AI, Inc.
Via Business Wire
News headline image
Tempus Announces Collaboration with Median Technologies to Integrate AI-Powered Lung Cancer Screening into the Pixel Platform
From Tempus AI, Inc.
Via Business Wire
News headline image
Tempus to Report Fourth Quarter and Full Year 2025 Financial Results on February 24
From Tempus AI, Inc.
Via Business Wire
News headline image
Ambry’s Contributions to MAVEs Support Thousands of Patient Reclassifications and Expand to New Genes
From Ambry Genetics
Via Business Wire
News headline image
Ambry Genetics Announces One Millionth Test Leveraging RNA to Improve Diagnostic Accuracy and Yield
From Ambry Genetics
Via Business Wire
News headline image
Tempus Reveals Its AI-Driven IPS Test More Accurately Predicts Immunotherapy Benefit Compared to Conventional Biomarkers
From Tempus AI, Inc.
Via Business Wire
News headline image
Tempus Announces the Launch of Paige Predict
From Tempus AI, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.